Celltrion logs record quarterly profit with Q3 OP surpassing $212 mn

(Celltrion)

Celltrion Inc. said Tuesday its consolidated operating profit for the third quarter reached 301 billion won ($212 million), up 44.9 percent from a year earlier, driven by robust global sales of high-margin products.

Revenue rose 16.3 percent on year to 1.02 trillion won, the company said in a regulatory filing.

Celltrion attributed the strong results to stable sales of its key products across global markets and expanding demand for newly launched high-profit biosimilars such as Remsima SC. Sales of high-margin products jumped 51 percent from a year earlier, lifting their share of total revenue from 42 percent in the third quarter of 2023 to 54 percent this year.

Among them, Stoboclo/Osenvelt and Omlyclo—both launched in the United States and Europe in the third quarter—posted a combined 50 billion won in sales in their debut quarter alone.

The company said the latest results also mark the final phase of its merger integration with Celltrion Healthcare, showing clear signs of normalization. Its cost-to-sales ratio fell 9 percentage points to 39 percent, entering the 30-percent range for the first time.

Celltrion also expects its recent acquisition of Eli Lilly’s biopharmaceutical manufacturing plant in Branchburg, New Jersey, to strengthen supply stability and reduce tariff risks while improving overall operational efficiency.

Celltrion said the effects of its merger have largely been resolved from the third quarter onward, adding that it expects stronger profit growth based on a normalized cost structure and higher operating leverage. The company also noted that it plans to launch additional high-margin biosimilars in major markets, including Europe, by year-end to accelerate both sales and earnings growth.